Insights
Search Results
Client Highlights
10.12.26
Wilson Sonsini Advises Armada Acquisition Corp. II on Business Combination with Evernorth Holdings
On October 9, 2026, Armada Acquisition Corp. II (Armada II), a special purpose acquisition company, and Evernorth Holdings (Evernorth), a digital asset treasury company building institutional access to the XRP economy, announced the completion of their business combination. Evernorth’s common stock is expected to begin trading on the Nasdaq Stock Market on October 12, 2026, under the ticker symbol “XRPN.” Investors included Arrington Capital, SBI Group, Ripple, Pantera Capital, Kraken, and GSR, among others.
Client Highlights
9.29.26
Wilson Sonsini Advises World Labs on $8.2 Billion Acquisition by AMD
On September 28, 2026, AMD, a global semiconductor company, announced it has entered into a definitive agreement to acquire World Labs, an AI model and research lab led by AI pioneer Dr. Fei-Fei Li. The acquisition will bring a world-class team of researchers and model experts to AMD, strengthening its ability to develop AI hardware, software, and systems. Wilson Sonsini Goodrich & Rosati is advising World Labs on the transaction.
Client Highlights
9.21.26
Firm Advises CoVet on Acquisition by IDEXX
On September 16, 2026, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised CoVet on the transaction.
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
Client Highlights
9.18.26
Wilson Sonsini Advises Superhuman on Acquisition of Fathom
On September 14, 2026, Superhuman, an AI productivity platform bringing AI to wherever people work, announced its acquisition of Fathom, an AI meeting partner trusted by hundreds of thousands of companies to capture, search, and act on what happens in meetings. Wilson Sonsini Goodrich & Rosati advised Superhuman on the transaction.
Client Highlights
8.25.26
Wilson Sonsini Advises Checkr on Acquisition of Truv
On August 18, 2026, Checkr, an AI-powered verification platform for high-stakes decisions, announced the acquisition of Truv, a consumer-permissioned income, employment, and asset verification company. Wilson Sonsini Goodrich & Rosati advised Checkr on the transaction.
Client Highlights
8.20.26
Wilson Sonsini Advises Highspot on Merger with Seismic
On August 18, 2026, Seismic, an AI-powered sales and revenue enablement platform, announced the completion of its merger with Highspot. Following a second request review, the merger obtained U.S. antitrust clearance, which allowed the transaction to close without any action by the Department of Justice Antitrust Division. The combined company will operate under the Seismic name and be led by Seismic Chief Executive Officer Rob Tarkoff. Wilson Sonsini Goodrich & Rosati advised Highspot on the transaction.
Client Highlights
8.17.26
Firm Advises Gravis Robotics on $200 Million Series A
On August 17, 2026, Gravis Robotics, a company retrofitting construction machines with autonomous technology, announced their Series A financing, with SoftBank investing $200 million in the company. The funding is the largest Series A in construction robotics history and will be used to scale autonomous machinery, bringing physical artificial intelligence (AI) directly to construction sites and embedding autonomous systems into heavy machinery fleets. Wilson Sonsini Goodrich & Rosati advised Gravis on the transaction.
Client Highlights
6.24.26
Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
5.14.26
Wilson Sonsini Advises Insider One on Acquisition of Bluecore
On May 13, 2026, Insider One, a leading agentic customer engagement platform, announced its acquisition of Bluecore, a leading retail marketing technology platform serving more than 400 U.S. enterprise brands. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Insider One on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Represents Investors in Windward Bio’s $165 Million Crossover Financing
On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included: